Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 20
Filter
Add more filters










Publication year range
1.
Pain ; 153(4): 850-861, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22321918

ABSTRACT

A nonphysiological repair of the lesioned nerve leading to the formation of neurinomas, altered nerve conduction, and spontaneous firing is considered the main cause of the events underlying neuropathic pain. It was investigated whether neural stem cell (NSCs) administration could lead to a physiological nerve repair, thus to a reduction of neuropathic pain symptoms such as hyperalgesia and allodynia in a well-established model of this pain (sciatic nerve chronic constriction injury [CCI]). Moreover, since we and others showed that the peripheral nerve lesion starts a cascade of neuroinflammation-related events that may maintain and worsen the original lesion, the effect of NSCs on sciatic nerve pro- and antiinflammatory cytokines in CCI mice was investigated. NSCs injected intravenously, when the pathology was already established, induced a significant reduction in allodynia and hyperalgesia already 3 days after administration, demonstrating a therapeutic effect that lasted for at least 28 days. Responses changed with the number of administered NSCs, and the effect on hyperalgesia could be boosted by a new NSC administration. Treatment significantly decreased proinflammatory, activated antiinflammatory cytokines in the sciatic nerve, and reduced spinal cord Fos expression in laminae I-VI. Moreover, in NSC-treated animals, a reparative process and an improvement of nerve morphology is present at a later time. Since NSC effect on pain symptoms preceded nerve repair and was maintained after cells had disappeared from the lesion site, we suggest that regenerative, behavioral, and immune NSC effects are largely due to microenvironmental changes they might induce at the lesion site.


Subject(s)
Hyperalgesia/surgery , Nerve Regeneration/physiology , Neural Stem Cells , Sciatic Neuropathy/surgery , Stem Cell Transplantation , Animals , Hyperalgesia/complications , Hyperalgesia/pathology , Injections, Intravenous , Male , Mice , Mice, Inbred C57BL , NIH 3T3 Cells , Neural Stem Cells/pathology , Neural Stem Cells/physiology , Pain Measurement/methods , Sciatic Neuropathy/complications , Sciatic Neuropathy/pathology , Stem Cell Transplantation/methods
2.
Eur J Pharmacol ; 650(2-3): 694-702, 2011 Jan 15.
Article in English | MEDLINE | ID: mdl-21050844

ABSTRACT

Treatment of diabetes complications remains a substantial challenge. The aim of this study was to explore the ability of the soy isoflavone genistein in attenuating the signs that follow diabetes onset: nociceptive hypersensitivity, oxidative and inflammatory state, nerve growth factor (NGF) decrease and vascular dysfunctions. Genistein (3 and 6 mg/kg) was administered to C57BL/6J streptozotocin diabetic mice from the 2nd till the 5th week after disease induction. The hind paw withdrawal threshold to mechanical stimulation (tactile allodynia) was evaluated by a von Frey filament. The oxidative stress was assessed measuring: reactive oxygen species by fluorimetric analysis, both the lipoperoxide content, as malondialdehyde, the antioxidant enzymatic activities spectrophotometrically and the glutathione content spectrofluorimetrically. Proinflammatory cytokines and NGF were measured in the sciatic nerve by enzyme-linked immunosorbent assay. Aortic inducible (iNOS) and endothelial nitric oxide synthase (eNOS) protein content was measured by western immunoblotting. Genistein relieved diabetic peripheral painful neuropathy, reverted the proinflammatory cytokine and reactive oxygen species overproduction, and restored the NGF content in diabetic sciatic nerve. Furthermore it restored the GSH content and the GSH and GSSG ratio, improved the antioxidant enzymes activities, decreased reactive oxygen species and lipoperoxide level in the brain and liver. Finally it restored the iNOS and eNOS content and the superoxide dismutase activity in thoracic aorta. Hyperglycaemia and weight decrease were not affected. Genistein is able to reverse a diabetes established condition of allodynia, oxidative stress and inflammation, ameliorates NGF content and the vascular dysfunction, thus suggesting its possible therapeutic use for diabetes complications.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Antioxidants/pharmacology , Diabetes Mellitus, Experimental/drug therapy , Diabetic Neuropathies/drug therapy , Genistein/pharmacology , Oxidative Stress/drug effects , Animals , Anti-Inflammatory Agents/therapeutic use , Antioxidants/therapeutic use , Aorta, Thoracic/drug effects , Aorta, Thoracic/metabolism , Brain/drug effects , Brain/metabolism , Cytokines/metabolism , Diabetes Mellitus, Experimental/complications , Diabetes Mellitus, Experimental/physiopathology , Diabetic Neuropathies/complications , Diabetic Neuropathies/physiopathology , Genistein/therapeutic use , Hyperalgesia/drug therapy , Hyperalgesia/metabolism , Hyperalgesia/physiopathology , Hyperglycemia/complications , Hyperglycemia/drug therapy , Inflammation/drug therapy , Inflammation/metabolism , Inflammation/physiopathology , Liver/drug effects , Liver/metabolism , Male , Mice , Mice, Inbred C57BL , Nerve Growth Factors/metabolism , Nitric Oxide Synthase Type II/metabolism , Nitric Oxide Synthase Type III/metabolism , Reactive Oxygen Species/metabolism , Sciatic Nerve/drug effects , Sciatic Nerve/metabolism , Superoxide Dismutase/metabolism
3.
J Pharmacol Sci ; 114(2): 158-67, 2010.
Article in English | MEDLINE | ID: mdl-20962454

ABSTRACT

Genistein is a naturally occurring plant-derived phytoestrogen, present in the human diet, known to possess some beneficial effects. The present study investigated the effect of genistein on neuroprotection evaluated through electroencephalographic and behavioural correlates in a model of global cerebral ischemia in gerbils. Over the dose range tested, genistein (3 and 10 mg/kg), given 5 min after recirculation antagonized the ischemia-induced electroencephalographic total spectral power decrease 7 days after ischemia; fully prevented ischemia-induced hyperlocomotion evaluated 1 day after ischemia; reversed ischemia-induced memory impairment evaluated through both nest building behaviour and object recognition test; decreased malondialdehyde overproduction in the brain, evaluated 7 days after reperfusion; and fully promoted the survival of pyramidal cells in the CA(1) hippocampal subfield. The selective antagonist for estrogen receptor-ß (ERß), 4-[2-phenyl-5,7-bis(trifluoromethyl) pyrazolo[1,5-a]pyrimidin-3-yl]phenol (PHTPP) given 30 min before carotid occlusion, fully prevented the neuroprotective effect of genistein at the dose of 3 mg/kg. These results demonstrate the neuroprotective effect of genistein through the activation of ERß and provide further grounds for the growing interest concerning the true potential of phytoestrogens as compounds to beneficially affect brain injury without having the disadvantages of estrogens.


Subject(s)
Estrogen Receptor beta/metabolism , Genistein/pharmacology , Neuroprotective Agents/pharmacology , Animals , Behavior, Animal/drug effects , Brain/drug effects , Brain/physiopathology , Brain Ischemia/physiopathology , Disease Models, Animal , Dose-Response Relationship, Drug , Electroencephalography/drug effects , Gerbillinae , Hippocampus/drug effects , Hippocampus/physiopathology , Male , Pyramidal Cells/drug effects , Pyramidal Cells/physiopathology
4.
Biochim Biophys Acta ; 1802(10): 924-33, 2010 Oct.
Article in English | MEDLINE | ID: mdl-19879943

ABSTRACT

Neuropathic pain refers to pain that originates from pathology of the nervous system. Diabetes, infection (herpes zoster), nerve compression, nerve trauma, and autoimmune diseases are examples of diseases that may cause neuropathic pain. Unfortunately no satisfactory treatment is yet available for this type of pain. This consideration has led to an explosion of interest for the underlying mechanisms, accompanied by a growing number of animal models. In recent years, most of the neuropathic pain models initially developed in the rat have been translated to mice in order to exploit the resource represented by genetically modified mice. Obviously the most useful animal models of pain would be ones in which the etiology of the pain would be endogenous and not induced by the experimenters: together with the classic models based on peripheral nerve ligation, in the last years other techniques are being developed that mimic more closely clinical pain syndromes, often by attempting to induce the disease associated to neuropathic pain. Although several variables must be taken into account when using animal models for mimicking clinical neuropathic pain, the huge number of models that are now reproducible and well characterized should help to reach important goals in the comprehension of mechanisms and to discover novel therapeutic target for this disease.


Subject(s)
Disease Models, Animal , Neuralgia/pathology , Animals , Humans , Mice , Neuralgia/etiology , Rats
5.
Phytother Res ; 23(12): 1678-84, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19441010

ABSTRACT

Neuropathy is the most common complication of diabetes and it is still considered to be relatively refractory to most of the analgesics. The aim of the present study was to explore the antinociceptive effect of a controlled cannabis extract (eCBD) in attenuating diabetic neuropathic pain. Repeated treatment with cannabis extract significantly relieved mechanical allodynia and restored the physiological thermal pain perception in streptozotocin (STZ)-induced diabetic rats without affecting hyperglycemia. In addition, the results showed that eCBD increased the reduced glutathione (GSH) content in the liver leading to a restoration of the defence mechanism and significantly decreased the liver lipid peroxidation suggesting that eCBD provides protection against oxidative damage in STZ-induced diabetes that also strongly contributes to the development of neuropathy. Finally, the nerve growth factor content in the sciatic nerve of diabetic rats was restored to normal following the repeated treatment with eCBD, suggesting that the extract was able to prevent the nerve damage caused by the reduced support of this neurotrophin. These findings highlighted the beneficial effects of cannabis extract treatment in attenuating diabetic neuropathic pain, possibly through a strong antioxidant activity and a specific action upon nerve growth factor.


Subject(s)
Cannabis/chemistry , Diabetic Neuropathies/drug therapy , Oxidative Stress/drug effects , Phytotherapy , Plant Extracts/therapeutic use , Animals , Antioxidants/pharmacology , Antioxidants/therapeutic use , Blood Glucose/analysis , Diabetes Mellitus, Experimental , Glutathione/metabolism , Hyperalgesia/physiopathology , Hyperglycemia/drug therapy , Lipid Peroxidation/drug effects , Liver/metabolism , Male , Nerve Growth Factor/metabolism , Plant Extracts/pharmacology , Rats , Rats, Wistar , Sciatic Nerve/metabolism
6.
J Neurochem ; 107(1): 230-40, 2008 Oct.
Article in English | MEDLINE | ID: mdl-18691380

ABSTRACT

There is great interest in soy isoflavones as alternatives to endogenous estrogens not only in hormonal pathologies, but also in inflammatory, neurodegenerative diseases, and pain. We investigated the effect of the isoflavone genistein on neuropathic pain. Genistein binds estrogen receptors (ER) with higher affinity for the ERbeta particularly expressed in neuronal and immune cells. Neuropathy was induced in mice by means of chronic sciatic nerve constriction, and the subcutaneous administration of genistein from the third day after the lesion reversed pain hypersensitivity in a time- and dose-dependent manner. This effect may have been due to the activation of classical nuclear receptor and/or anti-oxidant, anti-inflammatory, and immunomodulating properties of genistein. The fact that a specific ERbeta antagonist prevented both its anti-allodynic and anti-hyperalgesic action, whereas a specific ERalpha antagonist was ineffective and a non-selective ER antagonist only reversed the anti-allodynic effect, suggests the involvement of ERbeta. Antioxidant effects are also involved as the anti-nociceptive dose reversed the increase in reactive oxygen species and malondialdehyde in injured paw tissues, and increased the activity of anti-oxidant enzymes. The phytoestrogen had immunomodulatory and anti-inflammatory activities as it reduced peripheral and central nuclear factor-kappaB, nitric oxide system and pro-inflammatory cytokine over-activation. Taken together, our results suggest that genistein could ameliorate painful neuropathy by multiple mechanisms.


Subject(s)
Genistein/pharmacology , Inflammation/drug therapy , Oxidative Stress/drug effects , Peripheral Nervous System Diseases/drug therapy , Sciatic Neuropathy/drug therapy , Animals , Anti-Inflammatory Agents/pharmacology , Anti-Inflammatory Agents/therapeutic use , Antioxidants/pharmacology , Antioxidants/therapeutic use , Chronic Disease/drug therapy , Disease Models, Animal , Dose-Response Relationship, Drug , Ganglia, Spinal/drug effects , Ganglia, Spinal/metabolism , Ganglia, Spinal/physiopathology , Genistein/therapeutic use , Hyperalgesia/drug therapy , Hyperalgesia/metabolism , Hyperalgesia/physiopathology , Inflammation/metabolism , Inflammation/physiopathology , Inflammation Mediators/antagonists & inhibitors , Inflammation Mediators/metabolism , Ligation , Male , Mice , Mice, Inbred C57BL , Neurons, Afferent/drug effects , Neurons, Afferent/metabolism , Nociceptors/drug effects , Nociceptors/metabolism , Nociceptors/physiopathology , Oxidative Stress/physiology , Peripheral Nervous System Diseases/metabolism , Peripheral Nervous System Diseases/physiopathology , Phytoestrogens/pharmacology , Phytoestrogens/therapeutic use , Plant Extracts/pharmacology , Plant Extracts/therapeutic use , Receptors, Estrogen/drug effects , Receptors, Estrogen/metabolism , Sciatic Neuropathy/metabolism , Sciatic Neuropathy/physiopathology , Glycine max/chemistry , Treatment Outcome
7.
Pain ; 139(3): 541-550, 2008 Oct 31.
Article in English | MEDLINE | ID: mdl-18602217

ABSTRACT

Palmitoylethanolamide (PEA) is an endogenous lipid that is thought to be involved in endogenous protective mechanisms activated as a result of stimulation of inflammatory response. In spite of the well demonstrated anti-inflammatory properties of PEA, its involvement in controlling pain pathways still remains poorly characterized. On this basis, we tested the efficacy of PEA in vivo against a peculiar persistent pain, such as neuropathic one. PEA was administered i.p. to mice with chronic constriction injury of sciatic nerve (CCI) once a day for one week starting the day after the lesion. This therapeutic regimen evoked a relief of both thermal hyperalgesia and mechanical allodynia in neuropathic mice. Various selective receptor antagonists were used in order to clarify the relative contribution of cannabinoid, vanilloid and peroxisome proliferator-activated receptor to PEA-induced effects. The results indicated that CB(1), PPARgamma and TRPV1 receptors mediated the antinociception induced by PEA, suggesting that the most likely mechanism might be the so-called "entourage effect" due to the PEA-induced inhibition of the enzyme catalyzing the endocannabinoid anandamide (AEA) degradation that leads to an enhancement of its tissue levels thus increasing its analgesic action. In addition, the hypothesis that PEA might act through the modulation of local mast cells degranulation is sustained by our findings showing that PEA significantly reduced the production of many mediators such as TNFalpha and neurotrophic factors, like NGF. The findings presented here, in addition to prove the beneficial effects of PEA in chronic pain, identify new potential targets for analgesic medicine.


Subject(s)
Analgesics, Non-Narcotic/therapeutic use , Hyperalgesia/drug therapy , Mast Cells/drug effects , Nerve Growth Factors/metabolism , PPAR gamma/physiology , Palmitic Acids/therapeutic use , Receptor, Cannabinoid, CB1/physiology , Sciatica/drug therapy , TRPV Cation Channels/physiology , Amides , Analgesics, Non-Narcotic/pharmacology , Animals , Cytoplasmic Granules/metabolism , Drug Evaluation, Preclinical , Endocannabinoids , Ethanolamines , Hot Temperature/adverse effects , Hyperalgesia/etiology , Hyperalgesia/physiopathology , Ligation , Mast Cells/metabolism , Mice , NF-kappa B/physiology , PPAR alpha/antagonists & inhibitors , PPAR gamma/antagonists & inhibitors , Palmitic Acids/pharmacology , Physical Stimulation/adverse effects , Receptor, Cannabinoid, CB1/antagonists & inhibitors , Sciatic Nerve/injuries , Sciatica/physiopathology , Spinal Cord/chemistry , TRPV Cation Channels/antagonists & inhibitors , Touch , Tumor Necrosis Factor-alpha/analysis
8.
Phytother Res ; 22(8): 1017-24, 2008 Aug.
Article in English | MEDLINE | ID: mdl-18618522

ABSTRACT

This study aimed to give a rationale for the employment of phytocannabinoid formulations to treat neuropathic pain. It was found that a controlled cannabis extract, containing multiple cannabinoids, in a defined ratio, and other non-cannabinoid fractions (terpenes and flavonoids) provided better antinociceptive efficacy than the single cannabinoid given alone, when tested in a rat model of neuropathic pain. The results also demonstrated that such an antihyperalgesic effect did not involve the cannabinoid CB1 and CB2 receptors, whereas it was mediated by vanilloid receptors TRPV1. The non-psychoactive compound, cannabidiol, is the only component present at a high level in the extract able to bind to this receptor: thus cannabidiol was the drug responsible for the antinociceptive behaviour observed. In addition, the results showed that after chronic oral treatment with cannabis extract the hepatic total content of cytochrome P450 was strongly inhibited as well as the intestinal P-glycoprotein activity. It is suggested that the inhibition of hepatic metabolism determined an increased bioavailability of cannabidiol resulting in a greater effect. However, in the light of the well known antioxidant and antiinflammatory properties of terpenes and flavonoids which could significantly contribute to the therapeutic effects, it cannot be excluded that the synergism observed might be achieved also in the absence of the cytochrome P450 inhibition.


Subject(s)
Analgesics/pharmacology , Cannabinoids/pharmacology , Cannabis/chemistry , Hyperalgesia/drug therapy , Pain/drug therapy , Sciatic Neuropathy/drug therapy , ATP Binding Cassette Transporter, Subfamily B, Member 1/metabolism , Analgesics/chemistry , Animals , Cannabidiol/chemistry , Cannabidiol/pharmacology , Cannabinoids/chemistry , Cytochrome P-450 Enzyme Inhibitors , Cytochrome P-450 Enzyme System/metabolism , Disease Models, Animal , Liver/drug effects , Liver/enzymology , Male , Pain/etiology , Pain/physiopathology , Pain Threshold/drug effects , Plant Extracts/pharmacology , Rats , Rats, Wistar , Receptors, Cannabinoid/drug effects , Receptors, Cannabinoid/metabolism , Sciatic Neuropathy/complications , Sciatic Neuropathy/physiopathology , TRPV Cation Channels/metabolism
9.
Neurosci Lett ; 436(2): 210-3, 2008 May 09.
Article in English | MEDLINE | ID: mdl-18394803

ABSTRACT

The proinflammatory cytokine tumor necrosis factor-alpha (TNF) is an important mediator in neuropathic pain. We investigated the temporal pattern of TNF mRNA expression in the sciatic nerve, in dorsal root ganglia (DRG) and spinal cord in the mouse chronic constriction injury model of neuropathy with quantitative real-time polymerase chain reaction. Neuropathic pain-like behaviour was monitored by evaluating thermal hyperalgesia and mechanical allodynia. Pain-related behaviour and TNF expression were evaluated 6 h, 1, 3, 7 and 14 days after injury. Naive animals and sham-operated mice were used as controls. We found an early upregulation of sciatic nerve TNF mRNA levels in chronic constriction injury (CCI) and sham-operated animals 6 h after surgery: 1 day later TNF overexpression was present in CCI mice only and disappeared 3 days after injury. The mRNA cytokine levels were elevated in DRG 1 and 3 days after surgery in CCI animals only, while the cytokine was not modulated in the spinal cord. A significant hyperalgesia was present in CCI and sham-operated mice at 6 h and 1 day, while at later time point only CCI mice presented lower thresholds. Mechanical allodynia was already present only in CCI animals 6 h from surgery and remained constant up to the 14 th day. The results indicate that a transient early TNF upregulation takes place in peripheral nervous system after CCI that can activate a cascade of proinflammatory/pronociceptive mediators.


Subject(s)
Ganglia, Spinal/metabolism , Gene Expression Regulation/physiology , Neuralgia , Sciatic Nerve/metabolism , Tumor Necrosis Factor-alpha/metabolism , Analysis of Variance , Animals , Behavior, Animal , Disease Models, Animal , Hyperalgesia/physiopathology , Male , Mice , Mice, Inbred C57BL , Neuralgia/metabolism , Neuralgia/pathology , Neuralgia/physiopathology , Pain Threshold/physiology , RNA, Messenger/metabolism , Time Factors , Tumor Necrosis Factor-alpha/genetics
10.
Mol Cell Neurosci ; 37(3): 599-609, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18206390

ABSTRACT

Emerging evidence implicates gamma-aminobutyric acid type B (GABA(B)) receptors in peripheral nervous system (PNS) functions. In order to elucidate which biochemical, morphological and functional parameters of peripheral nerve fibers depend on GABA(B) receptors we studied GABA(B1)-deficient mice, which are devoid of functional GABA(B) receptors. Here, we show that GABA(B1)-deficient mice exhibit morphological and molecular changes in peripheral myelin, including an increase in the number of irregular fibers and increases in the expression levels of the myelin proteins PMP22 and P0. Moreover, the number of small myelinated fibers and small neurons of the lumbar dorsal root ganglia is higher in GABA(B1)-deficient mice than in wild-type littermates. We further show that GABA(B1)-deficient mice exhibit gait alterations and reduced allodynia. In summary, our findings implicate GABA(B) receptors in the PNS myelination process and raise the possibility that PNS alterations contribute to the sensory phenotypes of GABA(B1)-deficient mice.


Subject(s)
Gene Expression Regulation/genetics , Myelin Proteins/metabolism , Peripheral Nervous System/metabolism , Receptors, GABA-B/deficiency , Analysis of Variance , Animals , Calcitonin Gene-Related Peptide/metabolism , Gait/genetics , Hyperalgesia/genetics , Hyperalgesia/physiopathology , Male , Mice , Mice, Inbred BALB C , Mice, Knockout , Microscopy, Electron/methods , Myelin P0 Protein/metabolism , Nerve Fibers/metabolism , Nerve Fibers/ultrastructure , Pain Measurement , Sciatic Nerve/metabolism , Sciatic Nerve/ultrastructure , Ubiquitin Thiolesterase/metabolism
11.
Pain ; 137(1): 81-95, 2008 Jul.
Article in English | MEDLINE | ID: mdl-17900807

ABSTRACT

Neuropathic pain consequent to peripheral injury is associated with local inflammation and overexpression of nitric oxide synthases (NOS) and inflammatory cytokines in locally recruited macrophages, Schwann and glial cells. We investigated the time course and localization of nitric oxide synthases (NOS) and cytokines in the central (spinal cord and thalamus) and peripheral nervous system (nerve and dorsal root ganglia), in a mouse model of mononeuropathy induced by sciatic nerve chronic constriction injury. ATP is recognized as an endogenous pain mediator. Therefore we also evaluated the role of purinergic signalling in pain hypersensitivity employing the P2 receptor antagonist, pyridoxalphosphate-6-azophenyl-2',4'-disulphonic acid (PPADS), on pain behaviour, NOS and cytokines. The PPADS daily administration starting on day 3 after injury dose- and time-dependently decreased both tactile allodynia and thermal hyperalgesia. PPADS (25mg/kg) completely reversed nociceptive hypersensitivity and simultaneously reduced the increased NO/NOS system and IL-1beta in both peripheral (injured sciatic nerve and L4-L6 ipsilateral dorsal root ganglia) and central steps of nervous system (L4-L6 spinal cord and thalamus) involved in pain signalling. IL-6 was overexpressed only in the peripheral nervous system and PPADS prolonged administration reduced it in sciatic nerve. In conclusion, we hypothesize that NO/NOS and IL-1beta have a pronociceptive role in this neuropathy model, and that purinergic antagonism reduces pain hypersensitivity by inhibiting their overactivity.


Subject(s)
Interleukin-1beta/antagonists & inhibitors , Interleukin-6/antagonists & inhibitors , Nitric Oxide Synthase Type II/antagonists & inhibitors , Nitric Oxide Synthase Type I/antagonists & inhibitors , Peripheral Nervous System Diseases/prevention & control , Purinergic P2 Receptor Antagonists , Pyridoxal Phosphate/analogs & derivatives , Animals , Behavior, Animal/drug effects , Behavior, Animal/physiology , Central Nervous System/drug effects , Central Nervous System/enzymology , Central Nervous System/metabolism , Drug Delivery Systems , Interleukin-1beta/biosynthesis , Interleukin-6/biosynthesis , Male , Mice , Mice, Inbred C57BL , Nitric Oxide Synthase Type I/biosynthesis , Nitric Oxide Synthase Type II/biosynthesis , Pain/metabolism , Pain/physiopathology , Pain/prevention & control , Peripheral Nervous System/drug effects , Peripheral Nervous System/metabolism , Peripheral Nervous System Diseases/enzymology , Peripheral Nervous System Diseases/metabolism , Peripheral Nervous System Diseases/physiopathology , Pyridoxal Phosphate/pharmacology , Pyridoxal Phosphate/therapeutic use , Receptors, Purinergic P2/physiology
12.
Eur J Pharmacol ; 556(1-3): 75-83, 2007 Feb 05.
Article in English | MEDLINE | ID: mdl-17157290

ABSTRACT

Cannabidiol, the major psycho-inactive component of cannabis, has substantial anti-inflammatory and immunomodulatory effects. This study investigated its therapeutic potential on neuropathic (sciatic nerve chronic constriction) and inflammatory pain (complete Freund's adjuvant intraplantar injection) in rats. In both models, daily oral treatment with cannabidiol (2.5-20 mg/kg to neuropathic and 20 mg/kg to adjuvant-injected rats) from day 7 to day 14 after the injury, or intraplantar injection, reduced hyperalgesia to thermal and mechanical stimuli. In the neuropathic animals, the anti-hyperalgesic effect of cannabidiol (20 mg/kg) was prevented by the vanilloid antagonist capsazepine (10 mg/kg, i.p.), but not by cannabinoid receptor antagonists. Cannabidiol's activity was associated with a reduction in the content of several mediators, such as prostaglandin E(2) (PGE(2)), lipid peroxide and nitric oxide (NO), and in the over-activity of glutathione-related enzymes. Cannabidiol only reduced the over-expression of constitutive endothelial NO synthase (NOS), without significantly affecting the inducible form (iNOS) in inflamed paw tissues. Cannabidiol had no effect on neuronal and iNOS isoforms in injured sciatic nerve. The compound's efficacy on neuropathic pain was not accompanied by any reduction in nuclear factor-kappaB (NF-kappaB) activation and tumor necrosis factor alpha (TNFalpha) content. The results indicate a potential for therapeutic use of cannabidiol in chronic painful states.


Subject(s)
Cannabidiol/pharmacology , Cannabis/chemistry , Inflammation/drug therapy , Pain/drug therapy , Sciatic Neuropathy/drug therapy , Administration, Oral , Animals , Cannabidiol/administration & dosage , Cannabinoid Receptor Antagonists , Capsaicin/analogs & derivatives , Chronic Disease , Dinoprostone/blood , Freund's Adjuvant , Hyperalgesia/physiopathology , Inflammation/chemically induced , Lipid Peroxides/blood , Male , NF-kappa B/metabolism , Nitric Oxide/biosynthesis , Nitric Oxide Synthase/metabolism , Pain/metabolism , Pain/physiopathology , Pain Measurement , Rats , Rats, Wistar , Tumor Necrosis Factor-alpha/metabolism
13.
Br J Pharmacol ; 148(7): 1022-32, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16770320

ABSTRACT

An attractive alternative to the use of direct agonists at the cannabinoid receptor type 1 (CB1) in the control of neuropathic pain may be to potentiate the actions of endogenous cannabinoids. Thus, the effects of AM404, an inhibitor of anandamide uptake, were assessed in an experimental model of neuropathic pain in rats. Daily treatment with AM404 prevented, time- and dose-dependently, the development of thermal hyperalgesia and mechanical allodynia in neuropathic rats. Antagonists at cannabinoid CB1 or CB2 receptors, or at the transient receptor potential vanilloid type 1 receptor, each partially reversed effects induced by AM404. A complete reversal was obtained when the three antagonists were given together, suggesting that all three receptors are involved. AM404 treatment affected two pathways involved in the generation and maintenance of neuropathic pain, one mediated by nitric oxide (NO) and the other by cytokines. AM404 completely prevented the overproduction of NO and the overexpression of nNOS, inhibited the increase in tumour necrosis factor alpha (TNFalpha) and enhanced the production of interleukin-10. Both NO and TNFalpha are known to contribute to the apoptotic process, which plays an important role in the establishment of chronic pain states. AM404 treatment prevented the increase in the ratio between pro- and anti-apoptotic gene bax/bcl-2 expression observed in the spinal cord of neuropathic rats. Taken together, these findings suggest that inhibition of endocannabinoid uptake, by blocking the putative anandamide carrier, results in the relief of neuropathic pain and may represent a novel strategy for treating chronic pain.


Subject(s)
Analgesics , Apoptosis/drug effects , Arachidonic Acids/metabolism , Arachidonic Acids/pharmacology , Behavior, Animal/drug effects , Calcium Channel Blockers/metabolism , Cytokines/metabolism , Pain/psychology , Peripheral Nervous System Diseases/complications , Animals , Blotting, Western , Cannabinoid Receptor Antagonists , Endocannabinoids , Genes, bcl-2/genetics , Hot Temperature , Hyperalgesia/psychology , Male , Motor Activity/drug effects , NF-kappa B/pharmacology , Nitrates/metabolism , Nitrites/metabolism , Pain/etiology , Physical Stimulation , Polyunsaturated Alkamides , Rats , Rats, Wistar , Reverse Transcriptase Polymerase Chain Reaction , bcl-2-Associated X Protein/metabolism
14.
World J Gastroenterol ; 11(38): 5973-7, 2005 Oct 14.
Article in English | MEDLINE | ID: mdl-16273608

ABSTRACT

AIM: To evaluate the effects of gliadin on the oxidative environment in the "in vivo-like" model of a three-dimensional cell culture system. METHODS: LoVo cell line (intestinal adenocarcinoma) multicellular spheroids were treated with digested gliadin (with albumin used as a control). Spheroid volumes, cell viability and morphology, lactate dehydrogenase (LDH) release, content of reduced glutathione (GSH) and activity of GSH-related enzymes were examined. The data were statistically analyzed using the Student's t-test. was considered statistically significant. RESULTS: Gliadin reduced cell viability (from 20% to 60%) and led to morphological alterations characterized by apoptotic findings and cytoskeletal injuries. LDH activity increased. The content of GSH reduced (-20% vs controls), and activity of GSH-related enzymes was significantly inhibited. CONCLUSION: Gliadin treatment induces an imbalance in the antioxidative mechanism of cells cultured by the three-dimensional technique. This alteration may explain the cell damage directly caused by gliadin and the subsequent morphological abnormalities.


Subject(s)
Gliadin/pharmacology , Spheroids, Cellular/drug effects , Cell Line, Tumor , Cell Survival/drug effects , Glutathione/metabolism , Humans , Intestinal Neoplasms/drug therapy , Intestinal Neoplasms/metabolism , Intestinal Neoplasms/pathology , L-Lactate Dehydrogenase/metabolism , Microscopy, Electron, Scanning , Spheroids, Cellular/metabolism , Spheroids, Cellular/pathology
15.
Pain ; 116(1-2): 52-61, 2005 Jul.
Article in English | MEDLINE | ID: mdl-15936882

ABSTRACT

Many reports have shown the efficacy of cannabinoid agonists in chronic pain, whereas no report exists concerning the potential effect of cannabinoid antagonists following prolonged treatment. We tested the effects of repeated administration of the selective cannabinoid receptor type 1 (CB1) antagonist, SR141716 (rimonabant), in rats with chronic constriction injury of the sciatic nerve (CCI), an animal model of neuropathic pain. The repeated oral administration of SR141716 (1, 3 and 10 mg/kg, once a day for 1 week, from day 7 after the injury) dose dependently attenuated both thermal and mechanical hyperalgesia. A similar effect was observed in CCI wild-type mice, whereas SR141716 was unable to elicit pain relief in CB1 knockout mice, suggesting CB1 receptors involvement in the SR141716-induced antihyperalgesia. The antihyperalgesic activity of SR141716 was associated with a significant reduction of several pro-inflammatory and pro-nociceptive mediators such as tumor necrosis factor alpha (TNFalpha), prostaglandin-E2 (PGE2), lipoperoxide and nitric oxide (NO) levels. The histological analysis of sciatic nerve sections showed a marked degeneration of myelinated fibers in CCI rats, which was substantially reduced after repeated administration of SR141716. This suggests that the compound may favour myelin repair and consequently promote long-lasting functional recovery. This was confirmed by the maintenance of recovery for at least four weeks after treatment discontinuation. In conclusion, the present findings suggest that SR141716 is effective not only in alleviating neuropathic pain but also in favouring the nerve myelin repair.


Subject(s)
Cannabinoid Receptor Antagonists , Demyelinating Diseases/drug therapy , Pain/drug therapy , Piperidines/therapeutic use , Pyrazoles/therapeutic use , Sciatic Neuropathy/complications , Analysis of Variance , Animals , Blotting, Western/methods , Constriction , Demyelinating Diseases/etiology , Dinoprostone/blood , Enzyme-Linked Immunosorbent Assay/methods , Lipid Peroxides/metabolism , Male , Mice , Mice, Knockout/physiology , Nerve Tissue Proteins/metabolism , Nitrates/metabolism , Nitric Oxide Synthase/metabolism , Nitric Oxide Synthase Type I , Nitric Oxide Synthase Type II , Nitrites/metabolism , Pain/etiology , Pain Measurement/methods , Rats , Rats, Wistar , Reaction Time/drug effects , Receptors, Cannabinoid/deficiency , Rimonabant , Sciatic Nerve/drug effects , Sciatic Nerve/pathology , Staining and Labeling/methods , Tumor Necrosis Factor-alpha/metabolism
16.
Br J Pharmacol ; 143(2): 247-50, 2004 Sep.
Article in English | MEDLINE | ID: mdl-15313881

ABSTRACT

Cannabidiol (CBD), a nonpsychoactive marijuana constituent, was recently shown as an oral antihyperalgesic compound in a rat model of acute inflammation. We examined whether the CBD antihyperalgesic effect could be mediated by cannabinoid receptor type 1 (CB1) or cannabinoid receptor type 2 (CB2) and/or by transient receptor potential vanilloid type 1 (TRPV1). Rats received CBD (10 mg kg(-1)) and the selective antagonists: SR141716 (N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide) for CB1, SR144528 (N-[(1S)-endo-1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl]-5-(4-chloro-3-methylphenyl)-1-(4-methylbenzyl)pyrazole-3 carboxamide) for CB2 and capsazepine (CPZ) for TRPV1 receptors. The intraplantar injection of carrageenan in rats induced a time-dependent thermal hyperalgesia, which peaked at 3 h and decreased at the following times. CBD, administered 2 h after carrageenan, abolished the hyperalgesia to the thermal stimulus evaluated by plantar test. Neither SR141716 (0.5 mg kg(-1)) nor SR144528 (3 and 10 mg kg(-1)) modified the CBD-induced antihyperalgesia; CPZ partially at the lowest dose (2 mg kg(-1)) and fully at the highest dose (10 mg kg(-1)) reversed this effect. These results demonstrate that TRPV1 receptor could be a molecular target of the CBD antihyperalgesic action.


Subject(s)
Cannabidiol/therapeutic use , Capsaicin/analogs & derivatives , Disease Models, Animal , Hyperalgesia/drug therapy , Inflammation/chemically induced , Receptors, Drug/physiology , Administration, Oral , Animals , Camphanes/administration & dosage , Cannabidiol/antagonists & inhibitors , Cannabidiol/pharmacology , Capsaicin/pharmacology , Capsaicin/therapeutic use , Carrageenan/adverse effects , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical/methods , Drug Therapy, Combination , Hyperalgesia/chemically induced , Hyperalgesia/physiopathology , Inflammation/drug therapy , Italy , Male , Piperidines/administration & dosage , Pyrazoles/administration & dosage , Rats , Rats, Wistar , Receptor, Cannabinoid, CB1/administration & dosage , Receptor, Cannabinoid, CB1/antagonists & inhibitors , Receptor, Cannabinoid, CB2/administration & dosage , Receptor, Cannabinoid, CB2/antagonists & inhibitors , Receptors, Drug/drug effects , Receptors, Drug/therapeutic use , Rimonabant , Time Factors
17.
Naunyn Schmiedebergs Arch Pharmacol ; 369(3): 294-9, 2004 Mar.
Article in English | MEDLINE | ID: mdl-14963641

ABSTRACT

Cannabidiol, the major non-psychoactive component of marijuana, has various pharmacological actions of clinical interest. It is reportedly effective as an anti-inflammatory and anti-arthritic in murine collagen-induced arthritis. The present study examined the anti-inflammatory and anti-hyperalgesic effects of cannabidiol, administered orally (5-40 mg/kg) once a day for 3 days after the onset of acute inflammation induced by intraplantar injection of 0.1 ml carrageenan (1% w/v in saline) in the rat. At the end of the treatment prostaglandin E2 (PGE2) was assayed in the plasma, and cyclooxygenase (COX) activity, production of nitric oxide (NO; nitrite/nitrate content), and of other oxygen-derived free radicals (malondialdehyde) in inflamed paw tissues. All these markers were significantly increased following carrageenan. Thermal hyperalgesia, induced by carrageenan and assessed by the plantar test, lasted 7 h. Cannabidiol had a time- and dose-dependent anti-hyperalgesic effect after a single injection. Edema following carrageenan peaked at 3 h and lasted 72 h; a single dose of cannabidiol reduced edema in a dose-dependent fashion and subsequent daily doses caused further time- and dose-related reductions. There were decreases in PGE2 plasma levels, tissue COX activity, production of oxygen-derived free radicals, and NO after three doses of cannabidiol. The effect on NO seemed to depend on a lower expression of the endothelial isoform of NO synthase. In conclusion, oral cannabidiol has a beneficial action on two symptoms of established inflammation: edema and hyperalgesia.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Cannabidiol/administration & dosage , Cannabis , Carrageenan/toxicity , Edema/drug therapy , Administration, Oral , Animals , Dose-Response Relationship, Drug , Edema/chemically induced , Edema/metabolism , Hyperalgesia/chemically induced , Hyperalgesia/drug therapy , Hyperalgesia/metabolism , Male , Nitric Oxide/biosynthesis , Rats , Rats, Wistar
18.
Br J Pharmacol ; 137(4): 413-20, 2002 Oct.
Article in English | MEDLINE | ID: mdl-12359622

ABSTRACT

1. The anti-inflammatory activity of the endogenous fatty acid amide palmitoylethanolamide and its relationship to cyclo-oxygenase (COX) activity, nitric oxide (NO) and oxygen free radical production were investigated in the rat model of carrageenan-induced acute paw inflammation and compared with the nonsteroidal anti-inflammatory drug (NSAID) indomethacin. 2. Palmitoylethanolamide (1, 3, 5, 10 mg kg(-1); p.o.) and indomethacin (5 mg kg(-1); p.o.) were administered daily after the onset of inflammation for three days and the paw oedema was measured daily; 24 h after the last dose (fourth day) the rats were killed and the COX activity and the content of nitrite/nitrate (NO(2)(-)/NO(3)(-)), malondialdehyde (MDA), endothelial and inducible nitric oxide synthase (eNOS and iNOS) were evaluated in the paw tissues. 3. Palmitoylethanolamide had a curative effect on inflammation, inhibiting the carrageenan-induced oedema in a dose- and time-dependent manner. This effect was not reversed by the selective CB(2) receptor antagonist (N-[(1S)-endo-1,3,3-trimethylbicyclo[2.2.1]heptan-2yl]-5-(4-chloro-3-methylphenyl)-1-(4-methylbenzyl)pyrazole-3 carboxamide) (SR144528), 3 mg kg(-1) p.o. On the fourth day after carrageenan injection, COX activity and the level of NO(2)(-)/NO(3)(-), eNOS and MDA were increased in the inflamed paw, but iNOS was not present. Palmitoylethanolamide (10 mg kg(-1)) and indomethacin markedly reduced these increases. 4. Our findings show, for the first time, that palmitoylethanolamide has a curative effect in a model of acute inflammation. The inhibition of COX activity and of NO and free radical production at the site of inflammation might account for this activity.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Nitric Oxide/antagonists & inhibitors , Palmitic Acids/therapeutic use , Prostaglandin-Endoperoxide Synthases/metabolism , Acute Disease , Amides , Animals , Cyclooxygenase Inhibitors/pharmacology , Endocannabinoids , Ethanolamines , Fatty Acids/therapeutic use , Inflammation/chemically induced , Inflammation/drug therapy , Inflammation/enzymology , Male , Nitric Oxide/metabolism , Rats , Rats, Wistar
19.
Eur J Pharmacol ; 449(1-2): 61-9, 2002 Aug 02.
Article in English | MEDLINE | ID: mdl-12163107

ABSTRACT

The aim of this work was to investigate the effects of single and repeated administration of the endogenous cannabinoid anandamide (20 mg/kg i.p.) on cytochrome P450-mediated biotransformation in the rat. In liver microsomes from chronically treated rats, an increase in cytochrome P450 content and in the activity and immunoreactivity of cytochrome P450 reductase was detected. Immunoblot analysis of the hepatic microsomal proteins revealed an increase in the relative level of cytochrome P450 2B1/2 and 3A2. The activity of monooxygenase enzymes linked to specific cytochrome P450 isoforms was significantly enhanced. This increase in the content and activity of the cytochrome P450 system was also seen in liver microsomes from acutely treated rats; however, these increases were smaller than those seen after prolonged treatment. After acute treatment, the brain cytochrome P450 and b(5) content was increased, whereas after chronic treatment, only that of b(5) was enhanced. Cytochrome P450 reductase activity and its relative abundance were increased only in the brains of chronically treated rats. The present findings demonstrate that anandamide administration increased the metabolic activity of the cytochrome P450 system in rat liver and brain.


Subject(s)
Arachidonic Acids/pharmacology , Cytochrome P-450 Enzyme System/metabolism , Animals , Brain/drug effects , Brain/enzymology , Cannabinoid Receptor Modulators , Cytochromes b5/metabolism , Electrophoresis, Polyacrylamide Gel , Endocannabinoids , Immunoblotting , In Vitro Techniques , Isoenzymes/metabolism , Male , Microsomes/drug effects , Microsomes/enzymology , Microsomes, Liver/drug effects , Microsomes, Liver/enzymology , Polyunsaturated Alkamides , Rats , Rats, Sprague-Dawley , Stimulation, Chemical , Time Factors
20.
Br J Pharmacol ; 135(1): 181-7, 2002 Jan.
Article in English | MEDLINE | ID: mdl-11786493

ABSTRACT

1. The antiinflammatory activity of synthetic cannabinoid nabilone in the rat model of carrageenan-induced acute hindpaw inflammation was compared with that of the endocannabinoid palmitoylethanolamide and the nonsteroidal antiinflammatory drug indomethacin. 2. Preliminary experiments in rats used a tetrad of behavioural tests, specific for tetrahydrocannabinol-type activity in the CNS. These showed that the oral dose of nabilone 2.5 mg kg(-1) had no cannabinoid psychoactivity. 3. Intraplantar injection of carrageenan (1% w v(-1)) elicited a time-dependent increase in paw volume and thermal hyperalgesia. 4. Nabilone (0.75, 1.5, 2.5 mg kg(-1), p.o.), given 1 h before carrageenan, reduced the development of oedema and the associated hyperalgesia in a dose-related manner. Nabilone 2.5 mg kg(-1), palmitoylethanolamide 10 mg kg(-1) and indomethacin 5 mg kg(-1), given p.o. 1 h before carrageenan, also reduced the inflammatory parameters in a time-dependent manner. 5. The selective CB(2) cannabinoid receptor antagonist [N-[(1S)-endo-1,3,3-trimethyl bicyclo [2.2.1]heptan-2-yl]-5-(4-chloro-3-methylphenyl)-1-(4-methylbenzyl)pyrazole-3 carboxamide] (SR 144528), 3 mg kg(-1) p.o. 1 h before nabilone and palmitoylethanolamide, prevented the anti-oedema and antihyperalgesic effects of the two cannabinoid agonists 3 h after carrageenan. 6. Our findings show the antiinflammatory effect of nabilone and confirm that of palmitoylethanolamide indicating that these actions are mediated by an uncharacterized CB(2)-like cannabinoid receptor.


Subject(s)
Cannabinoids/pharmacology , Dronabinol/analogs & derivatives , Dronabinol/pharmacology , Inflammation/drug therapy , Palmitic Acids/pharmacology , Receptor, Cannabinoid, CB2 , Acute Disease , Amides , Animals , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Camphanes/pharmacology , Camphanes/therapeutic use , Cannabinoid Receptor Modulators , Cannabinoids/therapeutic use , Carrageenan/administration & dosage , Disease Models, Animal , Dronabinol/therapeutic use , Edema/chemically induced , Edema/prevention & control , Endocannabinoids , Ethanolamines , Hindlimb/drug effects , Hindlimb/pathology , Hyperalgesia/chemically induced , Hyperalgesia/prevention & control , Indomethacin/pharmacology , Male , Motor Activity/drug effects , Palmitic Acids/therapeutic use , Pyrazoles/pharmacology , Pyrazoles/therapeutic use , Rats , Rats, Wistar , Receptors, Cannabinoid , Receptors, Drug/antagonists & inhibitors
SELECTION OF CITATIONS
SEARCH DETAIL
...